All In Biotech

Drug Trial Radar · NCT07249905

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Jan 2028

Study completion Apr 2030

Sponsor

Sponsor type
Industry
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma

Conditions

  • Lymphoma
  • Waldenström Macroglobulinemia (WM)
  • DLBCL - Diffuse Large B Cell Lymphoma
  • PMBCL
  • HGBCL
  • FL Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Follicular Lymphoma (FL)

Interventions

  • MDX2003Drug

    MDX2003 intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A only- Identify the Maximum Tolerated Dose (MTD) for expansion for further development of MDX2003Time frame: 28 days
  2. All Study Parts: Adverse Events (AEs)Time frame: Baseline until 90 days after the participant has the last dose of MDX2003
  3. Part B only- Assess the preliminary anti-lymphoma activity of MDX2003Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Epworth HealthCare

    Richmond, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center - Beilinson Hospital

    Petah Tikva, Israel · Recruiting

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • Virgen del Rocío University Hospital

    Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.